61622-34-2 (头孢替胺,Cefotiam)

头孢替胺;头孢替安;7-[[(2-氨基-4-噻唑基)乙酰基]氨基]-3-[[[1-[(2-(二甲氨基)乙基]-1H-四唑-5-基]硫代甲基]-8-氧代-5-硫杂-1-氮杂双环[4.2.0]辛-2-烯-2-羧酸;头孢噻乙胺唑;盐酸头孢替安;

Cefotiam;(6r-trans)--oxo;)acetyl)amino)-3-(((1-(2-(dimethylamino)ethyl)-1h-tetrazol-5-yl)thio)methyl)-8;cgp14221e;8-[2-(2-amino-1,3-thiazol-4-yl)acetyl]amino-4-[[1-(2-dimethylaminoethyl)tetrazol-5-yl]sulfanylmethyl]-7-oxo-2-thia-6-azabicyclo[4.2.0]oct-4-ene-5-carboxylic acid;CEFOTIAM HCL;5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2-amino-4-thiazolyl)acetyl]amino]-3-[[[1-[2-(dimethylamino)ethyl]-1H-tetrazol-5-yl]thio]methyl]-8-oxo-, (6R,7R)-;5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2-amino-4-thiazolyl)acetyl]amino]-3-[[[1-[2-(dimethylamino)ethyl]-1H-tetrazol-5-yl]thio]methyl]-8-oxo-, (6R-trans)-;(6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)acetyl]amino]-3-[[1-[2-(dimethylamino)ethyl]tetrazol-5-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;(6R)-7t-[2-(2-amino-thiazol-4-yl)-acetylamino]-3-[1-(2-dimethylamino-ethyl)-1H-tetrazol-5-ylsul;7-[2-(2-aminothiazol-4-yl)acetamido]-3-[1-(2-N,N-dimethylaminoethyl)-tetrazol-5-yl]thiomethyl-3-cephem-4-carboxylic acid;CEFOTIAM HYDROCHLORIDE;Ceradolan;Ceradon;Haloapor;Prestwick0_000482;Aspil (TN);GTPL12254;7beta-(2-imino-4-thiazolin-4-yl)acetamido-3-{1-[2-(N,N-dimethylamino)ethyl]-1H-tetrazol-5-yl}thiomethyl-3-cephem-4-carboxylic acid;HY-B0734;SCE 963;66309-69-1;7beta-[ 2-(2-aminothiazol-4-yl) acetamido]-3-[1-(2-dimethylaminoethyl)-1H-tetrazol-5-yl]thiomethyl-3-cephem-4-carboxylic acid;DTXSID6022763;C21544;Prestwick1_000482;CEFOTIAM [JAN];Cefotiamum;UNII-91W6Z2N718;5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,7-[[(2-amino-4-thiazolyl)acetyl]amino]-3-[[[1-[2-(dimethylamino)ethyl]-1H-tetrazol-5-yl]thio]methyl]-8-oxo-, (6R,7R)-;SR-01000841230;BDBM50485561;Cefotiam (INN);CS-0009630;EN300-19766378;SCHEMBL11224134;(6R,7R)-7-{[(2-amino-1,3-thiazol-4-yl)acetyl]amino}-3-[({1-[2-(dimethylamino)ethyl]-1H-tetrazol-5-yl}sulfanyl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;CHEBI:355510;CEFOTIAM [INN];BSPBio_000343;Prestwick2_000482;QYQDKDWGWDOFFU-IUODEOHRSA-N;J01DC07;91W6Z2N718;(6R,7R)-7-[2-(2-Amino-thiazol-4-yl)-acetylamino]-3-[1-(2-dimethylamino-ethyl)-1H-tetrazol-5-ylsulfanylmethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid;CEFOTIAM [WHO-DD];7beta-(2-amino-1,3-thiazol-4-yl)acetamido-3-[({1-[2-(dimethylamino)ethyl]-1H-tetrazol-5-yl}sulfanyl)methyl]-3,4-didehydrocepham-4-carboxylic acid;(6R,7R)-7-(2-(2-aminothiazol-4-yl)acetamido)-3-((1-(2-(dimethylamino)ethyl)-1H-tetrazol-5-ylthio)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;61622-34-2;CTM;5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)acetyl)amino)-3-(((1-(2-(dimethylamino)ethyl)-1H-tetrazol-5-yl)thio)methyl)-8-oxo-, (6R-trans)-;SPBio_002264;NCGC00179594-01;NS00006913;Q3009984;SR-01000841230-2;Prestwick3_000482;AB00514684;Cefotiam [INN:BAN];Cefotiamum [INN-Latin];Cefotiam,(S);CGP 14221E;CEFOTIAM [MI];SCHEMBL149538;CHEMBL1296;(6R,7R)-7-[[2-(2-amino-1,3-thiazol-4-yl)acetyl]amino]-3-[[1-(2-dimethylaminoethyl)tetrazol-5-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;BPBio1_000379;(6R,7R)-7-[2-(2-amino-1,3-thiazol-4-yl)acetamido]-3-[({1-[2-(dimethylamino)ethyl]-1H-1,2,3,4-tetrazol-5-yl}sulfanyl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;BRD-K02275692-003-03-4;DB00229;(6R,7R)-7-{[(2-amino-1,3-thiazol-4-yl)acetyl]amino}-3-[({1-[2-(dimethylamino)ethyl]-1H-tetrazol-5-yl}thio)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;Aspil;D07648;J-700162;BRD-K02275692-300-02-6;BRD-K02275692-300-01-8;

MFCD00865087

QYQDKDWGWDOFFU-IUODEOHRSA-N

1S/C18H23N9O4S3/c1-25(2)3-4-26-18(22-23-24-26)34-7-9-6-32-15-12(14(29)27(15)13(9)16(30)31)21-11(28)5-10-8-33-17(19)20-10/h8,12,15H,3-7H2,1-2H3,(H2,19,20)(H,21,28)(H,30,31)/t12-,15-/m1/s1

S1CC(CSC2=NN=NN2CCN(C)C)=C(C(=O)O)N2C([C@H]([C@@H]12)NC(CC1=CSC(N)=N1)=O)=O

原料药。

方法1：0.824g化合物(I)、0.346g 1-(2-二甲氨基乙基)-1H-四唑-5-硫醇和0.168g碳酸氢钠溶于8ml水，在65 66℃下加热1.5h。用lmol/L盐酸酸化至Ph=3后，过滤。滤液用1mol/L****调至Ph=5.8，用XAD-2柱层析，洗脱液为从水缓慢变为40%甲醇。收集含产物的洗脱液，冻干得0.151g头孢替安，收率14%。其中1-(2-二甲氨基乙基)-1H-四唑-5-硫醇可由N-(2-二甲氨基乙基)异硫氰酸酯和叠氮钠在含水乙醇中加热而得。方法2：盐酸头孢替安酯的制备。1.83g环己醇和1.45g吡啶溶于30ml二氯甲烷，在干冰冷却和搅拌下，滴加2ml氯甲酸1-氯乙基酯。加毕，在室温下搅拌16h。用饱和氯化钠水溶液洗，无水硫酸镁干燥。减压蒸去溶剂，剩余液减压蒸馏，得到无色油状的碳酸卜氯乙基酯环己基酯，收率88%，沸点100～103℃(667Pa)。1.56g碳酸1-氯乙基酯环己基酯和5g碘化钠在50ml乙腈中，在60℃下搅拌70min。减压浓缩，剩余物用乙醚提取。提取液减压浓缩得油状的碳酸1-碘乙基酯环己基酯。3.6g头孢替安的钾盐(CTM-K)溶于30ml二甲基甲酰胺，在冰浴冷却和搅拌下，加入得到的碳酸1-碘乙基酯环己基酯的二甲基甲酰胺溶液。搅拌5min后，将反应液倾入用冰浴冷却的150ml 20%盐水和150ml乙酸乙酯的混合液。分出有机层，用饱和盐水洗，然后用40ml 1mol/L盐酸提取。水性提取液用MCI GELCHP 20P(75～150μrn，Mitsubishi Kasei)柱层析，用0.01mol/L盐酸和乙腈-0.0lmol/L盐酸(1...